VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 1, 2026
Stock Comparison
Gilead Sciences, Inc. vs HCA Healthcare, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisHCA Healthcare, Inc.
HCA · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into HCA Healthcare, Inc.'s moat claims, evidence, and risks.
View HCA analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 67 / 100 for HCA Healthcare, Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); HCA Healthcare, Inc. has 1 segment (100% in Hospitals and related healthcare entities).
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; HCA Healthcare, Inc. has 4 across 3.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
HCA Healthcare, Inc.
Hospitals and related healthcare entities
Acute care hospitals and outpatient healthcare services
United States (multi-state) and England (United Kingdom)
Patients and third-party payers
Provider operator
100%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
HCA Healthcare, Inc. strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
HCA Healthcare, Inc. segments
Full profile >Hospitals and related healthcare entities
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.